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ABStRACt
Neurofibroma is a benign peripheral nerve sheath tumour. It is one of the most frequent tumours of neural origin and 
its presence is one of the clinical criteria for the diagnosis of type 1 neurofibromatosis (NF-I). Neurofibromatosis type 
1 is an autosomal dominantly inherited disease due to an alteration in the long arm of chromosome 17. About 50% of 
NF-I patients have no family history of the disease. NF-I patients  have skin lesions (café au lait spots and neurofibromas) 
as well as bone malformations and central nervous system tumours. Diagnosis is based on a series of clinical criteria. 
Gingival neurofibroma in NF-I is uncommon. Treatment of neurofibromas is surgical resection. The  aim of this paper 
is to report a case of NF-I  with gingival involvement and to review the literature.
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RESUMEN
El neurofibroma es un tumor benigno, de los nervios periféricos, desarrollado a partir de la vaina neural. Representa uno de 
los tumores de origen neurógeno más frecuente y es uno de los criterios clínicos de diagnóstico de  neurofibromatosis tipo 1 
(NF-I). La NF-I es una enfermedad genética producida por una alteración en el brazo largo del cromosoma 17. La mitad 
de los casos tienen antecedentes familiares y el 50% son mutaciones nuevas. Los pacientes  con  NF-I principalmente pre-
sentan lesiones en la piel (manchas “café con leche” y neurofibromas), así como malformaciones óseas y tumores del sistema 
nervioso central. El diagnóstico de la enfermedad se basa en una serie de criterios clínicos. La aparición de neurofibromas 
en la encía en pacientes con NF-I es poco común El tratamiento de los neurofibromas es la escisión quirúrgica. El objetivo 
de este artículo es presentar un caso de NF-I con afectación neurofibromatosa de la encía maxilar, diagnosticado y tratado 
quirúrgicamente en nuestro Servicio de Cirugía Oral y Maxilofacial y realizar una revisión de la literatura.
Palabras clave: Neurofibromatosis tipo I, NF-I, neurofibroma, enfermedad de Von Recklinghausen, encía.
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INTRODUCTION
Neurofibroma is a benign peripheral nerve sheath tumour 
(1-6). Neurofibromas  arise from Schwann cells and peri-
neural fibroblasts (1,3-5,7,8). They may appear in patients 
with or without hereditary neurofibromatosis; in this last 
case they are called solitary neurofibromas (5). Two clinical 
forms of neurofibromatosis have been described: peripheral, 
type I (NF-I); and central, type II (NF-II) (1,5,8,9). These 
are two different diseases both from the clinical as the genetic 
point of view. (1,9). 
NF-I, also known as Von Recklinghausen’s disease, is a 
neurodermal dysplasia, first described by the pathologist 
Friederich Daniel Von Recklinghausen in 1882 (8,9). The 
pathologic alterations that define the disease begin in the 
embryogenic period, prior to the differentiation of  the 
neural crest (9-11). NF-I is more frequent (90% of cases) 
than NF-II. It is manifested mainly by skin lesions (café 
au lait spots, multiple neurofibromas), as well as by bone 
malformations and  central nervous system tumours (1,5,8-
10). It is the most frequent genetic human disease, affecting 
1:3000 newborn and one of  every 200 inhabitants with 
mental retardation (1,8-10,12).
The genetic alterations are localized in the long arm of 
chromosome 17 (9). NF-I is an autosomal dominantly in-
herited genetic disorder with a penetrance of almost 100% 
and a variable expression. 
However, about 50% of cases are sporadic as a consequen-
ce of spontaneous mutations. The disease has one of the 
highest rates of spontaneous mutations within the genetic 
diseases (1,5,6,8-13). There is no preference for gender or 
race in NF-I (1,9,10). Diagnosis of NF-I is based on clinical 
criteria (4,10) (Table 1).
In NF-II skin is generally less affected and bilateral acoustic 
neurinomas with or without  central nervous system tu-
mours constitute its main characteristic. Diagnosis is based 
on clinical criteria (5,14) (Table 1). NF-II (1:50.000) is less 
common than NF-I (1:5.000) and its genetic alteration is 
localized in the long arm of chromosome 22 (5,9,14).
20 to 60 % of  oral neurofibromas are associated with 
neurofibromatosis. Oral neurofibromas are present in about 
25 % of neurofibromatosis patients. Gingival affectation  is 
rare (6).
We report a case of a maxillary gingival neurofibroma in 
a NF-I patient.
At least two of these clinical criteria are needed to diagnose NF-I:
   -Six or more café au lait spots, >0,5cm diameter in prepuberal age and >15mm diameter in postpuberal age
   -Two or more neurofibromas of any kind or a plexiform neurofibroma. 
   -Axillary or inguinal freckles. 
   -Optic glioma.
   -Two or more Lisch nodules: pigmented bilateral hamartomas, that appear as cupular elevations on iris surface.
   -Distinctive bone lesion, sphenoidal dysplasia, dysplasia or thinning of long bones cortical. 
   -Relatives in first degree with NF-I. 
 At least one of these clinical criteria is needed to diagnose NF-II:
One relative in first degree with NF-II plus: a unilateral neural tumour of the 




Bilateral neural tumours of the 
eighth cranial nerve
-Juvenile cataract. 
Table 1. Clinical criteria for the diagnosis of NF-1 and NF-2.
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Fig 1. A: intraoral view showing a protruding lesion from tooth 2.4 to the ipsilateral tuberosity; B: “café au lait” spot on the 
right shoulder.
Fig. 2. A: surgical specimen and extracted tooth 2.8; B: bone view after resection of the lesion, frontal view; C: bone view after resection of 
the lesion, lateral view.
Fig. 3. Hematoxylin & Eosin. 100x. A: among the waved collagen fibers, neurofibroma cells can be appreciated with their nuclei 
showing a typical fascicular pattern of growth and serpentine; B: beneath the oral mucosa epithelium numerous tumor cells and 
capillary vessels can be seen among waved collagen fibers.
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CASE REPORt
A 21-year-old woman was referred to our department by 
her dentist for the evaluation of a two years evolution slow 
growing gingival hypertrophy. The lesion was soft and 
painless to palpation. It was located in the upper jaw and 
protruded in the buccal sulcus from the bicuspid region to 
the tuberosity (Fig.1.A). An orthopantomography showed 
no bony lesion. Seven years before the patient had had a 
neurofibroma resected in her left preauricular area. More 
than six café au lait spots over 15 mm diameter could be 
seen  throughout her skin (Fig. 1.B). Axillary and inguinal 
freckles were also present. A NF-I was diagnosed based on 
these clinical criteria.  The patient had no familiar history 
of NF-I. Under local anesthesia the lesion was partially 
resected and tooth 28 was extracted. Only the vestibular 
part of the lesion was resected, and the extension to the 
pterygopalatine fossa was left intact. Pathological report 
showed a neurofibroma (Fig.3). After eighteen months there 
are no signs or symptoms derived from the lesion.
DISCUSSION
NF-I is due to an alteration of the NF-I gene. This gene 
is a tumour suppressor gene located in the long arm of 
chromosome 17 (17q11.2) (1,10,12). The loss of this gene’s 
function due to a mutation determines an increase in cell 
proliferation and the development of tumours (1).
Pigmented lesions are a common manifestation in NF-I. 
These lesions usually appear during the first years of life 
or are present at birth, either as café au lait spots or as 
freckles (1,4,5,9,10). Café au lait spots are hyperpigmented 
maculae that may vary in color from light brown to dark 
brown  Their borders may be smooth or irregular. They may 
appear anywhere on the skin, but they are less common on 
the face (1). Inguinal and axillary freckles (Crowe´s sign) 
are frequently present (1,5). The patient here reported had 
more than six café au lait spots and bilateral axillary and 
inguinal freckles. 
Multiple skin neurofibromas as well as angiomas are 
also characteristic in NF-I (1,9,10). There exist two main 
clinical forms of  neurofibroma: localized and plexiform 
neurofibromas. Localized neurofibroma is the most frequent 
one in NF-I. It develops along a peripheral nerve as a focal 
mass with well defined margins. It is rarely present at birth 
but appears in late childhood or early adolescence (1). The 
number of localized neurofibromas generally increases with 
age, and there is an increase in size and number of the lesions 
during pregnancy and puberty (1,5). Although skin is the 
predominantly affected organ, some others such as stomach, 
bowels, kidney, urine bladder, larynx or heart may become 
affected. In the head and neck, the most frequently affected 
sites are scalp, cheek, neck and oral cavity (1). Plexiform 
neurofibroma spreads along the peripheral nerve and may 
affect some nervous rami (1,12). This is a poorly-circumscri-
bed and locally invasive tumour (12). About 21% of patients 
with NF-I are affected with plexiform neurofibromas (10). 
Morbidity of  plexiform neurofibromas in NF-I is high since 
they tend to grow until reaching a great size and producing 
disfigurement. Besides, the risk of malignization is between 
2 and 5% (1,12).   
Due to its diffuse involvement / appearance and soft con-
sistence, palpation of neurofibroma is similar to that of 
lipoma, vascular malformation, lymphangioma or rhab-
domyoma (5).
Bone involvement in NF-I may be due both to external 
resorption and to internal osteolytic defects. External re-
sorption may be due to the pressure applied on the bone by 
the neurofibroma, as it happens in the case here reported 
(Fig.2: B and C) (1,5). It is well known that in NF-I bone 
malformations such as kyphoscoliosis or pseudoarthrosis 
may appear, and the TMJ may be involved (5,9,11). Skele-
tal involvement is present in almost 40 % of patients with 
NF-I, being scoliosis the most common skeletal pathology 
(8,10,11).
Iris hamartoma, acoustic neurinoma, central nervous system 
tumours (glioma, glioblastoma), macrocephaly and mental 
retardation (up to 40% of cases) can also be found (9,10).
Oral cavity involvement appears in 66%-72% of the cases 
of  NF-I. Lengthening of fungiform papillae happens in 
50% of cases and is the most frequent finding. In 25% of 
neurofibromatosis patients oral neurofibromas can be seen. 
There is no racial, gender or age predilection for the develo-
pment of oral neurofibromas in NF-I. Neurofibromas may 
appear in every tissue, soft or hard, in the oral cavity. The 
most commonly affected site is the tongue (1,2,6,7,9,10). 
In the case here reported the neurofibroma was located in 
the gum, which is not a common location (1,6). Shapiro et 
al. state that gum involvement by neurofibroma in NF-I 
patients is 5% (referenced in Cunha el al. (1)). Localized 
oral neurofibromas usually appear as asymptomatic nodules 
covered by normally coloured mucosa (1,4,6,9). However, 
when adjacent to cranial nerves, they can impair motor 
function of facial or hypoglossal nerves or the sensitivity 
of trigeminal nerve (1,4,6). Gingival neurofibromas may 
cause dental malposition or impaction (1,9). In the case here 
reported the second molar could not erupt completely, and 
the wisdom tooth was totally included. NF-I patients may 
also show facial disfigurement due to hypo or hyperplasia of 
maxilla, mandible, malar bone and TMJ. Facial plexiform 
neurofibromas may also cause a facial asymmetry (1,10). 
Exophthalmos may also be present due to a dysplasia of 
the sphenoid major wing.  
Radiological findings in oral neurofibromas include 
mandibular channel, mandibular foramen and mental 
foramen widening (1,9).  Neurofibromas may seldom be 
primarily intraosseous; in that case they usually appear as 
a unilocular, well-defined radiolucency (1,6,7). In the case 
here reported no radiological alterations were found.  Most 
neurofibromas show low attenuation in CT scans, although 
some of them may show soft tissue density. Low density 
lesions contain a variable amount of Schwann cells, which 
are rich in lipids, cystic degeneration and xanthomatous alte-
rations. High density areas are thought to represent collagen 
rich or cellular areas. In MRI, lesions show a low signal in 
T1 and a high signal in T2, with a variable highlighting with 
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the contrast (8). A high peripheral signal with a low central 
signal in T2 weighted images (bull’s eye sign) is a typical sign 
of neurofibromas (6,8). A similar sign can be seen in CT; in 
this case there is a central high signal (8).
Histologically, neurofibromas are composed of a mixture of 
Schwann cells, perineural cells, and endoneural fibroblasts, 
and they are not capsulated (2,5,15). Schwann cells account 
for about 36 to 80% of lesional cells. These constitute the 
predominant cellular type and they usually have widened 
nuclei with an undulated shape and sharp corners. On elec-
tric microscopy Schwann cells can be seen embracing axons. 
These can be highlighted  with silver  or acetylcholinesterase 
staining or with immunohistochemical techniques when 
using the optic microscope. It is estimated that between 
0,7% and 31% of cells are perineural cells. In seldom cases 
this type of cells can predominate (15).
Neurofibromatous lesions usually evolve slowly, without 
pain, but during growth, puberty or pregnancy their evo-
lution may be accelerated (9).
Total or partial resection of neurofibromatous lesions is 
the treatment of  choice to solve aesthetic or functional 
problems; it is advisable to wait for treatment until growth 
has been completed thus diminishing the risk of recurren-
ce (4,6,9,10). Total resection with 1 cm margins whenever 
feasible is the treatment of choice for accessible and small 
tumours (5). Radiotherapy or chemotherapy are not re-
commended for treatment (5,9). Thalidomide has been 
used to treat pain in plexiform neurofibromas (4). There is 
no evidence that surgery favours malignant transformation. 
Malignant transformation rate of neurofibromas in NF-I 
is  3 to 5 % (1,9,10).
NF-I patients must receive genetic counselling since this is 
an autosomal dominantly inherited disease and the likeli-
hood of transmission to the children is 50% in both sexes 
(1). Malignant transformation to neurofibrosarcoma bears 
a very bad prognosis and distant metastases are frequent, 
being the mean survival of 15% at 5 years. Some authors 
state that recurrence may appear after surgical resection and 
that multiple recurrences increase the risk for malignant 
transformation (6).
It is important that oral and maxillofacial surgeons and 
dentists keep this disease under consideration when oral le-
sions characteristic of NF-I are present. These patients must 
be reviewed long term because of eventual complications, 
especially that of malignant transformation.
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